Evidence map›Paper›PMID 29310782›Full record

ArticleMethods in cell biology2018

The biochemistry and immunohistochemistry of versican.

Stephen P Evanko, Christina K Chan, Pamela Y Johnson, Charles W Frevert, Thomas N Wight

Open access · greenAbstract read
In one paragraph

Article in Methods in cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Use of Quantitative Digital Pathology to Measure Proteoglycan and Glycosaminoglycan Expression and Accumulation in Healthy and Diseased Tissues.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Review
  13. Single-cell RNA sequencing deconvolutes theInternational journal of biological sciences · 2021
    Article
  14. A Role for HAPLN1 During Phenotypic Modulation of Human Lung Fibroblasts In Vitro.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2020
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Stephen P EvankoMatrix Biology Program, Benaroya Research Institute, Seattle, WA, United States.
Christina K ChanMatrix Biology Program, Benaroya Research Institute, Seattle, WA, United States.
Pamela Y JohnsonMatrix Biology Program, Benaroya Research Institute, Seattle, WA, United States.
Charles W FrevertUniversity of Washington, Seattle, WA, United States.
Thomas N WightMatrix Biology Program, Benaroya Research Institute, Seattle, WA, United States. Electronic address: twight@benaroyaresearch.org.
Matrix Research (United States) · USBenaroya Research InstituteUniversity of Washington · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Thymic Stromal Lymphopoietin (TSLP) and Lung Inflammation and ImmP01HL098067 · NHLBI · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI FREVERT, CHARLES WAYNE · 2010 to 2014
$13.5M
Regulation of the Innate Immune Response by the Epithelium in AsthmaU19AI125378 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2016 to 2020
$9.2M
Impact of versican deficiency on the innate immune response to influenza virusR01AI136468 · NIAID · UNIVERSITY OF WASHINGTON · PI ALTEMEIER, WILLIAM A, FREVERT, CHARLES WAYNE · 2018 to 2022
$3.1M
NHLBI NIH HHS P01 HL098067NIAID NIH HHS R01 AI136468NIAID NIH HHS U19 AI125378NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

Versican is a chondroitin sulfate proteoglycan found in the extracellular matrix that is important for changes in cell phenotype associated with development and disease. Versican has been shown to be involved in cardiovascular disorders, as well as lung disease and fibrosis, inflammatory bowel disease, cancer, and several other diseases that have an inflammatory component. Versican was first identified as a fibroblast proteoglycan and forms large multimolecular complexes with hyaluronan and other components of the provisional matrix during wound healing and inflammation. The biology of versican has been well studied. Versican plays a major role in embryogenesis, particularly heart formation, where versican deletion proves lethal. The ability to purify versican to characterize and to use in experimental systems is vital to defining its role in development and disease. Protein expression systems have proven challenging to obtain milligram quantities of full-length versican. Here, we describe proteoglycan biochemical purification techniques that have been developed by others, but which we have adapted to use with our source tissues and cells. We also include methods for immunohistochemical localization and quantitation of versican in tissue sections.

Indexed as

AnimalsBlotting, WesternCell Culture TechniquesChromatography, GelEmbryonic DevelopmentExtracellular MatrixFibroblastsHeartHumansImage Processing, Computer-AssistedImmunohistochemistryMolecular ImagingTissue FixationVersicansVersicansAortaExtracellular matrixLungVascular smooth muscle cellsVersican

Identifiers

PMID29310782
PMCPMC6419768
OpenAlexW2769743022

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.